OzemPIC, Wegovy Novo Nordisk announces 9K hairstyles in restructuring – national

Novo Nordisk, the famous weight loss maker OzemPic and He wrapped upShe announced that it reaches about 9,000 workers in an attempt to “simplify operations”.

The company announced this on Wednesday, saying that it plans to reduce 11 percent of its global working power, as it will witness $ 1.7 billion of savings by the end of 2026. The company owns 78,400 employees.

The affected employees will be contacted by the company during the next few months, according to the company.

Mike Dosdar, President and CEO of Novo Nordsek, said in a press statement that this transformation was required because of how the markets were “evolving.”

“Our markets are developing, especially in obesity, because they have become more competitive and competing with the consumer,” said Duteard. “Our company must also develop. This means implanting performance-based culture, spreading our resources more effectively, and giving priority to investment as it will have the greatest effect-behind our pioneering treatment areas.”

1:51
Health issues: Wegovy agreed to reduce the risk of heart attacks

Novo Nordsek faced increasing competition, as Eli Lily exceeded the Danish company in obesity and diabetes markets.

Get the daily national news

Get the best news a day, addresses of political and economic affairs and current affairs, to your in the inbox once a day.

Zepbound from Eli Lilly Wegovy in the weekly recipes in the United States earlier this year, although wegovy recipes started to increase quickly during the summer, which narrows that bullets.

But the company also faced a wave of imitated imitated drugs.

In the midst of competition, Novo Nordisk is now trying to enhance production while meeting the increasing demand for its product and preparing to issue the form of the birth control pills from Wegovy.

“This is the first major step for the new executive director to simplify the Novo structure and redirect resources towards growth in diabetes and obesity,” said Michael Novod, head of stock research in Denmark in Nordic.

Doustdar told the Danish media in a call this week that the company is planning to re -invest savings from demobilization to drug pipelines and obesity in new markets, noting the increasing costs of a commercial strategy that includes the sale of medicines through consumer platforms such as health care to be more competitive.

In her press statement, Novo Nordisk said that the demobilization of workers will be at the company’s level, including the effects of employee areas.

& Copy 2025 Global News, a Division of Corus Entertainment Inc.